Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis

Gut

Volumn 48, Issue 1, 2001, Pages 62-69

  Johnson, C D ^a   Kingsnorth, A N ^b,g   Imrie, C W ^c   McMahon, M J ^d   Neoptolemos, J P ^b,e   McKay, C ^c   Toh, S K C ^a   Skaife, P ^b   Leeder, P C ^d   Wilson, P ^e   Larvin, M ^d   Curtis, L D ^f  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f British Biotechnology   (United Kingdom)

^g DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Acute pancreatitis; Lexipafant; Organ failure; Platelet activating factor; Systemic inflammatory response syndrome

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 8; LEXIPAFANT; PLACEBO; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM LESION; FEMALE; HUMAN; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOCYST; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACUTE DISEASE; ADULT; AGED; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; E-SELECTIN; FEMALE; HUMANS; IMIDAZOLES; INTERLEUKIN-8; LENGTH OF STAY; LEUCINE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PANCREATITIS; PLACEBOS; PLATELET ACTIVATING FACTOR; PROSPECTIVE STUDIES;

EID: 0035159658     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.1.62     Document Type: Article

References (36)

1. A clinically based classification system for acute pancreatitis
2. Acute pancreatitis - Medical management
3. Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gallstones
4. Early treatment of acute biliary pancreatitis by endoscopic papillotomy
5. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis
6. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis
7. Early antibiotic treatment in acute necrotizing pancreatitis
8. Current conservative treatment of acute pancreatitis: Evidence from animal and human studies
9. New perspectives on acute pancreatitis
10. Fatal pancreatitis, a consequence of excessive leukocyte stimulation?
11. Inflammatory mediators and cytokines - New aspects of the pathophysiology and assessment of severity of acute pancreatitis?
12. Relationship of necrosis to organ failure in severe acute pancreatitis
13. Inflammatory mediators in acute pancreatitis
14. Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis
15. Interleukin-1 receptor antagonist modifies the changes in vital organs induced by acute necrotizing pancreatitis in a rat experimental model
16. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody
17. Experimental acute pancreatitis induced by platelet activating factor in rabbits
18. Interleukin-10 prevents necrosis in murine experimental pancreatitis
19. Platelet activating factor: A phospholipid autocoid with diverse actions
20. Platelet-activating factor: A mediator of pancreatic inflammation during cerulein hyperstimulation
21. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats
22. Influence of a platelet-activating factor antagonist on severe pancreatitis in two experimental models
23. Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist
24. Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor
25. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis
26. EEC note for guidance: Good clinical practice for trials on medicinal products in the European Community
27. APACHE II: A severity of disease classification
28. Quantification of organ failure for clinical trials and clinical practice
29. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
30. APACHE II score for assessment and monitoring of acute pancreatitis
31. Prediction of outcome in acute pancreatitis: A comparative study of APACHE II, clinical assessment and multiple factor scoring systems
32. Influence of etiology on the course and outcome of acute pancreatitis
33. High early mortality rate from acute pancreatitis in Scotland, 1984-1995
34. Towards a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation
35. Acute pancreatitis as a model of sepsis